Barrow Seeks Participants for New Alzheimer’s Drug Trial

Barrow Neurological Institute is screening participants for a new clinical trial that will evaluate the drug troriluzole in people with mild to moderate Alzheimer’s disease.

The drug may have the potential to protect against, slow down, or improve memory and thinking problems by regulating the brain chemical glutamate. Dr. Anna Burke, director of the Alzheimer’s and Memory Disorders Program at Barrow, says excessive amounts of glutamate can cause damage to brain cells.

Barrow is one of more than 40 sites in the United States participating in the trial, called T2 PROTECT AD.

Read the full story on New Alzheimer’s drug trial starting at Barrow Neurological Institute
Read the full story in Ahwatukee Foothills News: Barrow seeks Alzheimer’s drug trial participants